CgA Therapeuticals' therapeutic programs are supported by a foundation of federally funded research investigating catestatin (CST), chromogranin A (CgA), aging, neurodegeneration, gastrointestinal dysfunction, metabolic disease, and related therapeutic applications. Current and selected prior awards relevant to the scientific development of the CST therapeutic platform are highlighted below.
Peptide and Peptidomimetic Therapy for Gastroparesis
CgA Therapeuticals, Inc. | 2026–2027
Award No. 1R43DK148298-01
Total Award: $350,195
Supports the preclinical development of CST and CST-based peptidomimetics as potential therapies for gastroparesis.
Catestatin Regulation of Tauopathy and Its Therapeutic Potentials
Veterans Medical Research Foundation of San Diego | 2025–2027
Award No. 1R21AG091126-01A1
Total Award: $405,625
Investigates the role of CST in tau pathology and its potential as a therapeutic approach for Alzheimer's disease and related tauopathies.
Catestatin and Its Mimetic Pharmacophore TKO-10-18 as Potential Therapies for Age-Associated Muscle Loss and Consequent Frailty
VA San Diego Healthcare System | 2023–2025
Award No. 1I21RX004398-01A1
Direct Costs: $229,580
Investigated CST and a CST-derived pharmacophore as potential therapeutic approaches for age-associated skeletal muscle loss and frailty.
Chromogranin A Is an Aging Risk Factor
Veterans Medical Research Foundation of San Diego | 2023–2025
Award No. 1R21AG078635-01A1
Total Award: $412,114
Investigated the role of chromogranin A in biological processes associated with aging and age-related disease.
Peptide Therapy for Age-Associated Gut Dysmotility
Veterans Medical Research Foundation of San Diego
2022–2024 Award No. 1R21AG080246-01
Total Award: $398,794
Evaluated peptide-based therapeutic approaches for age-associated gastrointestinal dysmotility
Catestatin Improves Glucose Homeostasis and Insulin Sensitivity in Diet-Induced Obese Mice
VA San Diego Healthcare System | 2017–2022
Direct Costs: $1,487,389
Investigated the role and therapeutic potential of CST in obesity-associated metabolic dysfunction, including impaired glucose homeostasis and insulin resistance.
